PURPOSE: The Oncotype DX Recurrence Score (RS), Prosigna Prediction Analysis of Microarray 50 (PAM50) Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) are used clinically for estimating risk of distant recurrence for patients receiving endocrine therapy. Discordances in estimates occur between them. We aimed to identify the molecular features that drive the tests and lead to these differences. PATIENTS AND METHODS: Analyses for RS, ROR, EP, and BCI were conducted by the manufacturers in the TransATAC sample collection that consisted of the tamoxifen or anastrozole arms of the ATAC trial. Estrogen receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative cases without chemotherapy treatment were incl...
Importance: Multiple molecular signatures are available for managing estrogen receptor (ER)–positiv...
Clinical variables and several gene signature profiles have been investigated for the prediction of ...
OBJECTIVE: Molecular tests predicting the risk of distant recurrence (DR) can be used to assist ther...
Importance:Multiple molecular signatures are available for managing estrogen receptor (ER)-positive ...
Purpose Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chem...
Oncotype Dx is used to determine the recurrence risk (RR) in patients with estrogen receptor positiv...
There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data...
Background Estimating distant recurrence (DR) risk among women with estrogen receptor-positive (ER+)...
BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen recep...
This work was funded by grants from Cancer Research UK (programme Grant C569-A16891), the Royal Mars...
Many genomic assays that assess recurrence risk in early breast cancer (EBC) are prognostic, but the...
Gene expression profiling tests such as the Oncotype DX (ODX) 21-gene recurrence score (RS) assay is...
Purpose: Hormone receptor-positive (HR + ) breast cancer is clinically and biologically heterogeneou...
BACKGROUND Breast cancer is a leading cause of cancer-related death in women worldwide. Despite e...
PURPOSE: To test the validity of OncoMasTR Molecular Score (OMm), OMclin1, and OncoMasTR Risk Score ...
Importance: Multiple molecular signatures are available for managing estrogen receptor (ER)–positiv...
Clinical variables and several gene signature profiles have been investigated for the prediction of ...
OBJECTIVE: Molecular tests predicting the risk of distant recurrence (DR) can be used to assist ther...
Importance:Multiple molecular signatures are available for managing estrogen receptor (ER)-positive ...
Purpose Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chem...
Oncotype Dx is used to determine the recurrence risk (RR) in patients with estrogen receptor positiv...
There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data...
Background Estimating distant recurrence (DR) risk among women with estrogen receptor-positive (ER+)...
BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen recep...
This work was funded by grants from Cancer Research UK (programme Grant C569-A16891), the Royal Mars...
Many genomic assays that assess recurrence risk in early breast cancer (EBC) are prognostic, but the...
Gene expression profiling tests such as the Oncotype DX (ODX) 21-gene recurrence score (RS) assay is...
Purpose: Hormone receptor-positive (HR + ) breast cancer is clinically and biologically heterogeneou...
BACKGROUND Breast cancer is a leading cause of cancer-related death in women worldwide. Despite e...
PURPOSE: To test the validity of OncoMasTR Molecular Score (OMm), OMclin1, and OncoMasTR Risk Score ...
Importance: Multiple molecular signatures are available for managing estrogen receptor (ER)–positiv...
Clinical variables and several gene signature profiles have been investigated for the prediction of ...
OBJECTIVE: Molecular tests predicting the risk of distant recurrence (DR) can be used to assist ther...